Cheap tirzepatide, expensive semaglutide
Almost every seller here charges more for tirzepatide than for semaglutide, because the drug costs more to source. WeightRx does the opposite by a wide margin, and does not explain why on the page that prints both figures.
That is not a reason to distrust the number, but it is a reason to ask what the semaglutide lane actually is before assuming the two are the same kind of offer. The page treats them identically, and the treatment table gives them the same status marker.
One figure, six products
The treatment table lists six products. Two are marked as available. Four are marked coming soon. Every one of the five products that is not the tirzepatide carries the same figure, including brand-name injections and tablets that would normally cost several times a compounded preparation.
A single price repeated across six SKUs that cannot all plausibly cost the same is the shape of a placeholder rather than a quoted rate. Our record carries the figure because the seller publishes it, and the qualifier says where else it appears.
An asterisk that resolves to nothing
Both live figures carry an asterisk. The page was read in full and no footnote defining it appears anywhere in the visible text. What is stated is that the rate is locked for the full term, which implies a term the page never names.
Seventy-eight of the one hundred and fifty-eight sellers here carry a headline figure that is promotional, introductory, or conditioned on a commitment the number does not disclose. This is a variant: the condition is acknowledged and then left blank.
One hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all, and this is one of them. The pharmacies are described as dozens of quality-vetted partners rather than named, which puts it among the one hundred and twenty-six sellers here that name no compounding pharmacy.
WeightRx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (compounded) | $83/moas low as, per month, carrying an asterisk the page never defines; the FAQ states "Your rate is locked for your full term", so a term commitment is implied and never named | September 2026source |
| Semaglutide (compounded) | $250/moper month, same undefined asterisk; the identical figure is printed beside five further products on the same page - Foundayo tablets, Wegovy injection, Wegovy tablets and the Zepbound KwikPen - and four of those five are labelled Coming soon | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See WeightRx's current price →Good fit if
- Buyers who want compounded tirzepatide and are willing to ask what term the locked rate refers to.
- Readers who prefer a price table on a public page to an intake questionnaire.
- Anyone who wants the cash-pay position stated plainly, which this seller does.
Look elsewhere if
- Anyone who wants to know which company they are contracting with; three different entity or address statements appear across the site.
- Buyers who want brand-name products now rather than when the coming-soon labels come off.
- Readers who need the compounding pharmacy named.
- Anyone who needs a service-area list before starting.
How this review was verified
- Read the homepage price table and the Terms of Use on 6 September 2026, comparing the requested path to the effective path on every fetch and running a nonsense path against the host in the same run; that control returned a clean not-found status with eighty characters of text.
- Joined adjacent text nodes before matching prices, so a figure split across elements could not be missed, and counted how many products carry the semaglutide figure rather than assuming it belonged to semaglutide alone.
- Searched the full extracted text of the priced page for a footnote defining the asterisk and found none; the absence is recorded as an absence rather than as a condition we guessed at.
- Recorded both the Texas operator named in the Terms and the New York corporation in the footer, without resolving which is the contracting party.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.